An update on the ‘danger theory’ in inhibitor development in hemophilia A-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An update on the ‘danger theory’ in inhibitor development in hemophilia A

Published:2019-04-25 Issue:5 Volume:12 Page:335-344
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Schep Sarah J.¹,Boes Marianne²,Schutgens Roger E.G.¹,van Vulpen Lize F.D.¹^ORCID

Affiliation:

1. Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

2. Department of Pediatrics, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Publisher

Informa UK Limited

Subject

Hematology

Link

https://tandfonline.com/doi/pdf/10.1080/17474086.2019.1604213

Reference100 articles.

1. The Diagnosis and Management of Congenital Hemophilia

2. A close insight to factor VIII inhibitor in the congenital hemophilia A

3. The epidemiology of inhibitors in haemophilia A: a systematic review

4. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

5. The burden of inhibitors in haemophilia patients

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and treatment-related risk factors of inhibitor development after intensive FVIII replacement for major orthopaedic surgery in previous treated haemophilia A;Journal of Orthopaedic Surgery and Research;2024-06-16

2. Elevated memory T‐cell conversion in a preclinical mouse model of hemophilia A;European Journal of Immunology;2024-06-14

3. The spleen is the major site for the development and expansion of inhibitor producing-cells in hemophilia A mice upon FVIII infusion developing high-titer inhibitor;Thrombosis Research;2023-11

4. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

5. Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication;Blood Advances;2023-04-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3